Combating the global threat of microbial infections
We translate transformational innovations into therapies and diagnostic tests for infectious diseases.
We translate transformational innovations into therapies and diagnostic tests for infectious diseases.
Curatix is fighting the rise of multi-drug resistant strains like Candida auris by developing new anti-fungal drugs as well as antimicrobial adjuvants that render pathogens more susceptible to existing antifungal drugs.
Infection by tick-borne Babesia parasites is on the rise in the US and globally, but current treatments fall short. We are translating a groundbreaking dual culture/animal model to propel treatments and diagnostics from the lab to the clinic and field/epidemiological studies.
We are leveraging our expertise in the biology and pathogenesis of fungal pathogens and parasites to develop advanced diagnostic tests to improve disease surveillance and speed time to treatment.
Front and center: Pallavi Singh, Curatix Founder Choukri Ben Mamoun, Stefano Lonardi, Karine le Roch and colleagues report a comprehensive suite of multi-omics analyses that reveal evolution, drug sensitivity and virulence mechanisms of this parasite, which causes a malaria-like disease in humans and animals.
Please feel free to reach out if interested in discussing potential partnerships or translational research opportunities.
Copyright © 2023 Curatix Therapeutics - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.